Revasc

RSS

desirudin

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Revasc has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 29/07/2014

Authorisation details

Product details
Name
Revasc
Agency product number
EMEA/H/C/000104
Active substance
desirudin
International non-proprietary name (INN) or common name
desirudin
Therapeutic area (MeSH)
Venous Thrombosis
Anatomical therapeutic chemical (ATC) code
B01AE01
Publication details
Marketing-authorisation holder
Canyon Pharmaceuticals Ltd.
Revision
12
Date of issue of marketing authorisation valid throughout the European Union
09/07/1997
Contact address
Canyon Pharmaceuticals Limited
7th Floor
52-54 Gracechurch Street
London
EC3V 0EH
United Kingdom

Product information

23/01/2012 Revasc - EMEA/H/C/000104 - IAIN/0031/G

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.

Assessment history

How useful was this page?

Add your rating